FDA-2018TIHIIHVWJUQAXC97K8XF1

Republic of the Philippines
Department of Health
FOOD AND DRUG ADMINISTRATION
Civic Drive, Filinvest Corporate City, Alabang, Muntinlupa City

FDA Food and Drug Administration PHILIPPINES

CERTIFICATE OF PRODUCT REGISTRATION

Pursuant to the provisions of Republic Act (R.A.) No. 3720 as amended, known as the Foods, Drugs, Devices and Cosmetics Act, and consistent with R.A. No. 6675, known as the Generics Act of 1988, and R.A. No. 9711, otherwise known as the Food and Drug Administration Act of 2009, the product described hereunder has been found to conform with the requirements and standards for marketing authorization of pharmaceutical products per existing regulations in force as of date hereof.

Registration Number	:	**DR-XY46280**
Generic Name	:	Glutathione
Brand Name	:	Tationil 600
Dosage Strength & Form	:	600 mg Lyophilized Powder for Injection (IM/IV)
Pharmacologic Category	:	Antidote
Classification	:	Prescription Drug (Rx)
Approved Shelf-life	:	36 months
Storage Condition	:	Store at temperatures not exceeding 30°C
Packaging	:	10 mL USP Type I clear, colorless glass vial sealed with bromo butyl rubber stopper and yellow aluminum seal + USP Type I clear, colorless glass ampoule Water for Injection x 4 mL as diluent (Box of 10's)
Manufacturer	:	Friends Pharma (Pvt.) Ltd. 31-Km, Ferozepur Road, Lahore, Pakistan
Importer	:	Raquel-Abbas Pharmaceuticals & General Merchandise No. 17 Madre Isabella di Rocis St., Multinational Village, Moonwalk, Parañaque City
Distributor	:	Raquel-Abbas Pharmaceuticals & General Merchandise No. 17 Madre Isabella di Rocis St., Multinational Village, Moonwalk, Parañaque City

The marketing authorization shall be valid until **08 March 2023** subject to the conditions listed on the reverse side. No change in the formulation, labelling and commercial presentation of this product shall be made at any time during the effectivity of this registration without prior written approval of this Office.

This marketing authorization is subject to suspension, cancellation or recall should any violation of R.A. No. 3720, R.A. No. 6675 and R.A. No. 9711 and/or regulations issued thereunder involving the product be committed.

Witness My Hand and Seal of this Office, this **08 March 2018**.

By Authority of the Director-General
Per FDA Order No. 2016-005

ATTY. KATHERINE M. AUSTRIA-LOCK
Office-in-Charge
Center for Drug Regulation and Research

REG. STATUS	:	**Monitored Release (MR)**
AMOUNT	:	**Php15,150; Php25,000; Php5,555**
OR NUMBER	:	**557033; 914619; 906622**
DATE	:	**9-June-2014; 8-Dec-2017; 12-Dec-2017**
CODE	:	**215**
BAR CODE DOC TRACK	:	2 0 1 4 0 5 2 9 1 0 4 9 0 3

TÜVRheinland CERTIFIED ISO 9001:2008 Management System

FDA-0287225

Renewal DTN: 202303171104058
O.R. No.: 3242023123435615
Date Issued: 24 MAR 2023

The validity of this CPR is extended for one year from 09 MARCH 2025 to 08 MARCH 2026 unless earlier cancelled or revoked by this Office.

18 March 25
MARIA CECILIA C. MATIENZO
Director IV
Center for Drug Regulation and Research

Registration Number : DR-XY46280

SPECIAL CONDITION:

Provided that nothing in the registration of the product herein granted shall be interpreted or construed as an endorsement or representation by FDA, that Registrant has the right or privilege to the use of the name or brand so registered; Registrant hereby agrees and affirms to indemnify and/or hold FDA free and harmless against any and all third-party claims on infringement of patent, trademark or intellectual property right arising from the registration of the product.

	A	This is subject to batch notification.
	B	This is subject to lot release certification.
X	C	This is subject to compliance with the requirements under FDA Circular No. 2013-004 for Monitored Release (MR) drug products.
X	D	Subject to post-marketing surveillance of the marketing authorization holder's strict compliance to the Generic Labeling Requirements following the applicable provisions of A.O No. 2016-0008 for drug products for human use and A.O. No. 105 s. 1991 for veterinary drug products.
	E	For renewal registration, submit a satisfactory Bioequivalence Study Report or Biowaiver (whichever is applicable) within the validity of this CPR in accordance with FDA Circular No. 2016-019.
	F	Dangerous Drug - To be prescribed by PDEA S-2 licensed practitioner in a DOH (yellow) prescription form. It is a habit-forming drug.
	G	Dangerous Drug - To be prescribed by PDEA S-2 licensed practitioner in a personalized ordinary prescription. It is a habit-forming drug.
	H	Patient Information Leaflet - Appropriate information for the consumers shall be written in Filipino and/or local dialects, as appropriate.
	I	For renewal registration, submit a Certificate of Good Manufacturing Practice (GMP) Compliance of Foreign Drug Manufacturer(s) within the validity of this CPR in accordance with A. O. No. 2013-0022 and FDA Circular No. 2014-016.
	J	Review of the submitted Bioequivalence Study Report or Biowaiver, whichever is applicable, shall be completed by the FDA within the validity of this CPR; correspondingly, this CPR shall be revoked if product interchangeability has not been established.
	K	Subject to compliance to the post-approval commitments detailed in the letter accompanying this CPR.

REMARKS:

Renewal DTN: 202303171104058
O.R. No.: 3242023123435615
Date Issued: 24 MAR 2023

The validity of this CPR is extended for one year from 09 MAR 2024 to 08 MAR 2025 unless earlier cancelled or revoked by this Office.

JESUSA JOYCE N. CIRUNAY, RPh
Director IV
Center for Drug Regulation and Research
24 MAR 2023

Renewal DTN: 202303171104058
O.R. No.: 3242023123435615
Date Issued: 24 MAR 2023

The validity of this CPR is extended for one year from 09 MAR 2024 to 08 MAR 2025 unless earlier cancelled or revoked by this Office.

JESUSA JOYCE N. CIRUNAY, RPh
Director IV
Center for Drug Regulation and Research
08 MAR 2024